ID   TC587
AC   CVCL_ZV62
DR   cancercelllines; CVCL_ZV62
DR   Wikidata; Q98133175
RX   PubMed=32014918;
CC   Population: Japanese.
CC   Doubling time: ~36 hours (PubMed=32014918).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Asp816Tyr (c.2446G>T); ClinVar=VCV000013860; Zygosity=Unspecified (PubMed=32014918).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Unspecified (PubMed=32014918).
CC   Sequence variation: Mutation; HGNC; HGNC:18118; RSF1; Simple; p.Pro1133Leu (c.3398C>T); Zygosity=Unspecified (PubMed=32014918).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala347Asp (c.1040C>A); ClinVar=VCV000043587; Zygosity=Unspecified (PubMed=32014918).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C8107; Ovarian yolk sac tumor
DI   ORDO; Orphanet_876; Yolk sac tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 19-12-24; Version: 8
//
RX   PubMed=32014918; DOI=10.21873/anticanres.14007;
RA   Iwasaki T., Kohashi K., Ohno M., Taguchi T., Oda Y.;
RT   "Establishment and characterization of a novel primitive yolk sac
RT   tumour cell line, TC587.";
RL   Anticancer Res. 40:759-766(2020).
//